Book a Meeting

Anti-CMV Antibody, Half-Life Extended (AES-0622-ZP1205) (CAT#: AES-0622-ZP1205) Datasheet

Target
CMV
Description
Creative Biolabs enhances the binding ability of the anti-CMV antibody to FcRn by modifying the Fc of the antibody, thereby increasing the half-life of the antibody.
Applications
Increase the half-life of antibodies
Technology
Fc engineering technology

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CMV antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Background
Sevirumab; 138660-96-5; MSL-109; SDZ MSL 109; EV2 7; MSL-109; 55 kDa immediate-early protein 1; 45 kDa immediate-early protein 2; CMV; Envelope glycoprotein B; gB; Glycoprotein B; HHV 5; HHV5; Human herpesvirus 5; IE1; IE2; UL122; UL122 regulatory protein IE2; UL123;
Antibody Clone
AES-0622-ZP1205
Description
Creative Biolabs enhances the binding ability of the anti-CMV antibody to FcRn by modifying the Fc of the antibody, thereby increasing the half-life of the anti- antibody.

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany

ISO 9001 Certified - Creative Biolabs Quality Management System.